AZD1390: ATM Kinase Inhibitor Workflow

AZD1390 is a potent and selective ATM kinase inhibitor designed for experiments that interrogate DNA damage response signaling. Its most direct use-case is radiosensitization: inhibit ATM before or during ionizing radiation, then measure checkpoint failure, DNA damage persistence, micronuclei, apoptosis, or clonogenic survival. The approach is especially relevant to cancer research involving glioma, lung cancer, replication stress, and defects in DNA double-strand break signaling.

The compound also offers a useful bridge to new work on non-canonical DNA structures. The reference study on human REV1 and DHX36 shows that G-quadruplex DNA creates a replication challenge that is managed through coordinated helicase activity, translesion synthesis control, and suppression of single-stranded DNA gaps. AZD1390 does not replace those mechanistic assays; instead, it can be used as a pathway perturbation to test how ATM activity responds when G-quadruplex tolerance is compromised.

Setup and principle: what AZD1390 reveals

ATM is activated by DNA double-strand breaks and helps organize repair, cell-cycle checkpoint regulation, and survival decisions. Blocking this kinase can make radiation-induced lesions more consequential because cells have less capacity to pause replication or coordinate repair. The AZD1390 product information reports a cellular IC50 of 0.78 nM, effective ATM inhibition at 3 nM in glioblastoma LN18 cells, and enhanced radiation-associated effects at 10 nM in NCI-H2228 lung cancer cells.

These values should be treated as reference points rather than universal working concentrations. Cellular uptake, ATM abundance, p53 status, radiation schedule, plating density, and assay endpoint can shift the active window. A concentration-response design is therefore more informative than a single-dose experiment. Include vehicle controls, untreated controls, radiation-only controls, and AZD1390-only controls so that radiosensitization can be distinguished from baseline cytotoxicity.

In this context, AZD1390 can generate a functional DNA double-strand break repair inhibitor phenotype without directly inhibiting every repair enzyme. That distinction matters: reduced phospho-ATM signaling may alter checkpoint behavior even when lesion formation, end resection, or repair pathway engagement is not completely eliminated. A robust study combines an early signaling readout with later measurements of cell fate.

Key Innovation from the Reference Study

The reference study by Ketkar and colleagues identifies a direct interaction between the C-terminal domain of REV1 and a newly defined C-terminal region of the G-quadruplex helicase DHX36. The work supports a two-tiered mechanism: REV1 helps coordinate G-quadruplex resolution and replication tolerance, while also restraining PrimPol-driven synthesis and limiting persistent single-stranded DNA gaps. Loss of REV1 shifted fork elongation toward a PrimPol-dependent mechanism, increased nuclear G-quadruplex signal, amplified ATM/ATR signaling, and sensitized cells to G-quadruplex stabilization.

This finding translates into practical assay choices. First, compare parental, REV1-deficient, and REV1-rescued cells rather than interpreting a single cell line as representative. Second, pair G-quadruplex stabilization with measurements of ATM pathway activation, such as phospho-ATM or downstream checkpoint markers, while separately quantifying replication progression and ssDNA gaps. Third, use co-immunoprecipitation or proximity-based assays to test whether prolonged G-quadruplex stress changes REV1–DHX36 association. AZD1390 can be added as a controlled ATM perturbation to determine which phenotypes are ATM-dependent and which persist despite ATM suppression.

Why this cross-domain matters, maturity, and limitations

The bridge from G-quadruplex replication biology to tumor radiosensitization is scientifically plausible but not yet equivalent to a validated combination therapy. The reference study establishes REV1–DHX36 coordination and its relationship to ATM/ATR signaling; the product dossier establishes AZD1390 activity in radiation-oriented glioma and lung cancer models. It does not prove that REV1–DHX36 disruption is the reason AZD1390 radiosensitizes tumors. Treat this connection as a hypothesis-driven experimental framework, and use genetic rescue, pathway markers, and orthogonal replication assays to avoid over-attribution.

Step-by-step experimental workflow

1. Establish the cellular response window

Begin with a small dose matrix in LN18, NCI-H2228, or another disease-relevant model. Record viability without radiation before evaluating combination effects. This prevents a concentration that is intrinsically toxic from being mislabeled as a radiosensitizer. If p53-mutant glioma cells are available, include them as a mechanistically informative comparison because enhanced effects have been reported in that context.

2. Prepare the compound consistently

AZD1390 is a solid with a reported molecular weight of 477.57 and is insoluble in water. For a practical stock, dissolve it in DMSO with gentle warming and ultrasonic treatment, then make single-use aliquots. A 10 mM stock corresponds to approximately 4.78 mg/mL, below the reported DMSO solubility of at least 19.6 mg/mL. Avoid repeated freeze–thaw cycles and do not plan long-term storage of dilute working solutions.

3. Separate drug timing from radiation timing

Run at least two schedules: pretreatment before radiation and post-radiation addition. Pretreatment is useful for testing checkpoint suppression, whereas post-treatment can reveal effects on damage processing or recovery. Keep the radiation dose, medium volume, confluence, and time from irradiation to replating constant. For clonogenic assays, normalize survival to the relevant untreated or vehicle-treated control rather than comparing raw colony counts across different plating densities.

4. Build a layered readout panel

Use early phospho-signaling measurements to verify target engagement, then add cell-cycle and damage-persistence endpoints. In NCI-H2228 cells, the dossier describes radiation-associated G2 arrest, micronuclei formation, and apoptosis with AZD1390. In glioma models, combine viability or clonogenic survival with γH2AX or 53BP1 foci, micronuclei, and apoptosis markers. For G-quadruplex experiments, add nuclear G4 imaging, DNA-fiber analysis, and ssDNA-gap measurements where technically feasible.

Protocol Parameters

The following are executable pilot conditions for assay development. The concentration and animal-dose reference points reflect the product dossier; timing, radiation, and sampling intervals should be optimized for the selected model.

• Stock preparation: Prepare a 10 mM AZD1390 stock in DMSO, warm at 20–25°C, and sonicate for 5–10 minutes until uniformly dissolved; make aliquots at 50–100 µL per tube.
• Cellular concentration screen: Test 3, 10, and 30 nM AZD1390 for 1 hour before radiation, maintaining the final DMSO concentration at or below 0.1% v/v.
• Radiation matrix: Compare 0, 2, 4, and 6 Gy ionizing radiation with matched AZD1390 and vehicle controls; collect early signaling samples at 1–6 hours.
• Delayed phenotyping: Measure cell-cycle distribution, micronuclei, and apoptosis at 24, 48, and 72 hours after irradiation, using identical cell numbers and staining volumes between conditions.
• In-vivo reference arm: If reproducing the reported rat orthotopic lung-brain tumor model, evaluate the 20 mg/kg oral AZD1390 plus radiation condition only under approved animal protocols and with formulation, exposure, and tolerability verification.

Advanced applications and comparative advantages

AZD1390 is valuable because it can connect pathway biochemistry with a treatment-relevant phenotype. A broad DNA-damaging agent may increase lesions while simultaneously activating several stress pathways, making interpretation difficult. A selective ATM inhibitor offers a narrower perturbation: researchers can ask whether checkpoint attenuation changes radiation survival, replication-fork behavior, or the response to G-quadruplex stabilization.

For glioblastoma radiosensitization, compare radiation alone with AZD1390 alone and the combination across p53 backgrounds. A strong combination phenotype should be supported by more than one endpoint, such as reduced clonogenic survival together with increased micronuclei or apoptosis. For lung cancer models, examine whether G2 accumulation is transient or followed by mitotic catastrophe. These distinctions can reveal whether ATM inhibition primarily delays the cell cycle or converts unrepaired damage into lethal chromosome abnormalities.

The article AZD1390: Amplifying ATM Inhibition for Translational Impact complements this workflow by emphasizing translational assay design and G-quadruplex-related repair questions. The more focused AZD1390: ATM Control at Stalled G4 Forks extends the same logic toward replication-fork assays. Finally, REV1–DHX36 Interaction Enables G-Quadruplex DNA Replication Fidelity provides the mechanistic foundation for testing whether G4-associated ATM signaling is altered when REV1 or DHX36 function changes. Together, these resources form an extension pathway rather than interchangeable evidence.

Troubleshooting and optimization tips

Unexpected precipitation or variable potency

Because AZD1390 is water-insoluble, precipitation after dilution can create a false low-dose condition. Inspect wells microscopically, prepare concentrated intermediate dilutions in DMSO, add them slowly with mixing, and keep vehicle percentage constant. If visible precipitate remains, reduce the intermediate dilution step or validate the actual free-drug exposure analytically.

High toxicity without radiation

Reduce the concentration range and confirm that the vehicle control is not affecting growth. Check confluence and passage number, since stressed or overconfluent cultures can exaggerate ATM-inhibitor sensitivity. A useful radiosensitization experiment requires a sublethal AZD1390 condition in the absence of radiation.

No combination effect

Verify target engagement before changing the radiation dose. If phospho-ATM suppression is absent, review compound preparation, exposure time, and cell permeability. If ATM inhibition is confirmed but survival is unchanged, test a different radiation schedule, extend the observation period, or use a second phenotype such as micronuclei or clonogenic recovery. Do not infer that the REV1–DHX36 pathway is uninvolved from a negative short-term viability result.

G4 signal increases but ATM markers do not

G-quadruplex accumulation and ATM activation may not peak at the same time. Run a time course and include replication-fork or ssDNA-gap measurements. The reference study indicates that prolonged G4 stabilization can uncouple DHX36 from REV1 and alter helicase localization, so a single fixed time point may miss the relevant transition.

Future outlook

The most informative next step is not simply to increase AZD1390 potency, but to define which replication-stress phenotypes depend on ATM after REV1–DHX36 coordination is disrupted. Paired genetic backgrounds, time-resolved signaling, DNA-fiber analysis, and rescue experiments can distinguish checkpoint effects from direct defects in G4 processing. In translational models, the reported dose-dependent tumor inhibition and stronger response at 20 mg/kg with radiation provide a rationale for integrating pharmacodynamic markers with tumor growth rather than relying on growth curves alone.

Used with appropriate controls, AZD1390 can therefore function as both a radiosensitizer for glioma and lung cancer and a selective ATM inhibitor for DNA damage response research. Its strongest contribution is experimental clarity: it allows researchers to test how ATM signaling shapes the consequences of stalled replication, G-quadruplex tolerance, and radiation-induced DNA damage without treating these processes as a single mechanism.